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Abstract
Background: An evaluation of standard automated perimetry (SAP) and short wavelength automated perimetry (SWAP) for
the central 10–2 visual field test procedure in patients with age-related macular degeneration (AMD) is presented in order to
determine methods of quantifying the central sensitivity loss in patients at various stages of AMD.
Methods: 10–2 SAP and SWAP Humphrey visual fields and stereoscopic fundus photographs were collected in 27 eyes of 27
patients with AMD and 22 eyes of 22 normal subjects.
Results: Mean Deviation and Pattern Standard Deviation (PSD) varied significantly with stage of disease in SAP (both
p,0.001) and SWAP (both p,0.001), but post hoc analysis revealed overlap of functional values among stages. In SWAP,
indices of focal loss were more sensitive to detecting differences in AMD from normal. SWAP defects were greater in depth
and area than those in SAP. Central sensitivity (within 1u) changed by 23.9 and 24.9 dB per stage in SAP and SWAP,
respectively. Based on defect maps, an AMD Severity Index was derived.
Conclusions: Global indices of focal loss were more sensitive to detecting early stage AMD from normal. The SWAP
sensitivity decline with advancing stage of AMD was greater than in SAP. A new AMD Severity Index quantifies visual field
defects on a continuous scale. Although not all patients are suitable for SWAP examinations, it is of value as a tool in
research studies of visual loss in AMD.
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Introduction
Age-related macular degeneration (AMD) is the third leading
cause of blindness in the world and accounts for blindness in 8.7%
of the global population [1]. Due to the increasing elderly
population, it is expected that 17.8 million individuals in the US
will be affected by 2050 [2]. The functional loss of central vision
due to age-related macular degeneration (AMD) is well docu-
mented. However of the studies investigating visual field loss in
AMD, some reported reduced threshold values [3,4,5,6,7] whilst
others did not [8,9,10,11] and these discrepant findings may reflect
differing methods of fundus grading and analyses. In addition no
attempt has previously been made to quantify the visual field loss
at each stage of severity of AMD. Such knowledge improves our
understanding of the natural disease process in terms of visual
function and the development of retinal changes. The early
identification of patients who would benefit from treatment may
help improve visual prognosis.
Past studies evaluating central visual field loss in AMD using
non-standard procedures have shown foveal flicker sensitivity to be
affected in early AMD [12] and greater flicker perimetry deficits
[13]. A number of other techniques have also found functional
deficits in AMD, including scotopic sensitivity testing [14,15,16],
multifocal electroretinogram [17,18] and preferential hyperacuity
perimetry [19]. However these techniques are not readily available
for clinical use.
Evidence of short-wavelength sensitivity (SWS) pathway vul-
nerability in retinal disease suggests the usefulness of short-
wavelength automated perimetry (SWAP) in monitoring AMD
progression. This is supported by findings of SWS pathway deficits
in AMD [20,21,22], SWAP sensitivity loss in eyes with soft drusen
[6] and in eyes with diabetic retinopathy [23], and the earlier
detection of glaucomatous visual field progression by SWAP
[24,25]. Although the use of 30–2 and 24–2 SWAP fields is not
clinically widespread due to their greater variability compared to
SAP fields [26], the flatter profile of the hill of vision for the 10–2
field allows for more accurate statistical interpretation and greater
capability in the detection of focal loss [27].
The aims of the study were to quantify the central visual field
loss in a cross-section of AMD patients in standard automated
perimetry (SAP) and SWAP. Secondary aims were to evaluate the
location of visual field loss in AMD and the appropriate statistical
measures that describe visual field loss.
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Subjects
Subjects were recruited from Birmingham and Midland Eye
Centre and the Aston University Eye Clinic. Based on 10u SWAP
variability values from the normative database and from a
previous study in patients [28], a sample of 7 at each stage would
give 80% confidence of detecting a difference of 1.34 dB in mean
sensitivity. The sample consisted of 27 patients (mean age
68.867.8 years, range 46–84 years, 8 males, 19 females) with a
diagnosis of AMD and 22 age-matched healthy controls (mean age
67.267.5 years, range 49–78 years, 13 males, 9 females). Subjects
had SAP experience but were naı ¨ve to SWAP. All study eyes met
the inclusion criteria of refraction less than 65.00 DS and
62.00 DC, clear ocular media (Lens Opacity Classification
System III [29] ,NC3, NO3, C1 and P1), no pseudophakia,
Figure 1. Stages of AMD. Example fundus images of stages of AMD. Top left: Stage 0, top right: Stage 1, middle left: Stage 2, middle right: Stage 3,
bottom left: Stage 4 atrophic AMD, bottom right: Stage 4 neovascular AMD.
doi:10.1371/journal.pone.0039944.g001
Table 1. Definitions of the Mutually Exclusive Stages of AMD.
Stage Definition
Stage 0 No signs of AMD, or presence of hard drusen (,63mm) only
Stage 1 Soft distinct drusen ($63mm) only, or pigmentary abnormalities only
Stage 2 Soft indistinct drusen ($125mm) only, or soft distinct drusen ($63mm) with pigmentary abnormalities
Stage 3 Soft indistinct ($125mm) with pigmentary abnormalities
Stage 4 Atrophic or neovascular AMD
Stages of disease were derived based a longitudinal 6.5 year epidemiologic study of progression rates of AMD [31]. See example images in Figure 1.
doi:10.1371/journal.pone.0039944.t001
Visual Field Loss in AMD
PLoS ONE | www.plosone.org 2 June 2012 | Volume 7 | Issue 6 | e39944tonometry ,21 mmHg (Pulsair, Keeler, Windsor, UK), normal
optic nerve head appearance (assessed by ophthalmologist, JMG),
no family history of glaucoma, no history of ocular disease other
than untreated AMD, no ocular trauma, no systemic disease, no
systemic medication known to influence the visual field, pupil
diameters .3 mm and no congenital colour vision defect.
Corrected visual acuity was at least 0.1logMAR in each eye, in
the normal group and ranged between 0–1logMAR in the patient
group. Four patients (of 31 who initially attended) were excluded
from the study for non-foveal fixation, as assessed using the
ophthalmoscope cross-hair fixation target or due to inability to
complete a visual field test.
Written informed consent was obtained from each subject and
the study had approval from the Aston University Human
Sciences Ethical Committee and the NHS West Midlands
Research Ethics Committee. The study followed the Tenets of
the Declaration of Helsinki.
AMD Grading
Stereoscopic 30u fundus images were acquired (EOS 10D, 6.3
megapixels, Canon, Tokyo, Japan) and stored as high quality
JPEG files (307262048) and viewed on a 20.10 4is:3 monitor
(120061600 pixel resolution), using a prismatic stereoviewer.
Image grading [30] and stage of disease [31] (Table 1; Figure 1)
was determined in a random order. Subjects who had any
gradable features [30] were defined as belonging to the AMD
patient group. All grading was determined by independent,
masked graders (JMG & JHA), using custom written software
(written in Liberty BASIC, Shoptalk Systems, Framingham, MA,
USA), which mapped the circular grading grid to the fundus
image and incorporated a measurement tool.
Perimetry
All subjects underwent visual field testing on the dominant eye,
as determined by the hole-in-the-card test [32]. Each subject
underwent SAP and SWAP 10–2 visual field examinations with
the Humphrey Field Analyser 750 (Carl Zeiss Meditec, Dublin,
CA, USA) on two occasions. For SAP, the stimulus size was 0.43u
(Goldmann III) and the background luminance was 10 cd/m
2. For
SWAP, blue (440 nm) 1.72u (Goldmann V) stimuli were presented
on a yellow (.530 nm) 100 cd/m
2 background. SITA Standard
and FASTPAC algorithms were employed for the SAP and SWAP
fields, respectively, in order to mimic clinical practice as closely as
possible. FASTPAC is the recommended strategy in SWAP [26]
and SITA SWAP is not available for the 10–2 field. Visits were
separated by 11 days, and the results from the first visit were
discarded to account for the learning effect.
Before each examination, patients underwent three minutes of
background adaptation. Fixation losses, false negative and false
positive responses were less than 33%. Regular rest periods were
given during and between examinations. The decision to include
SAP (SITA standard) fields with false positives .15% and ,33%
was based on careful assessment of the video monitor gaze tracking
function and the other parameters of fixation monitoring.
Analysis
Visual field change with stage of AMD was determined using
the mean deviation (MD), pattern standard deviation (PSD),
number of pattern deviation (PD) defects and local spatial
variability (LSV). The LSV is a global index calculated as the
root mean square of pointwise sensitivity differences between the
raw and median filtered visual field [33]. All PD defects ,5% were
considered significant. The SAP MD and PSD were weighted
indices from the HFA printout. Unweighted SWAP indices were
calculated from a normal database collected previously. It
consisted of 65 normal subjects (age 22–79) who performed 10–
2 SWAP visual fields (FASTPAC). The normative data was
analysed using univariate linear regression to give the age-
corrected normal values at each stimulus location and the
confidence intervals were calculated to derive probability defects.
Figure 2. Boxplots representing the change in the visual field with stage of severity of disease. The change in MD (dB), PSD (dB), LSV and
number of PD defects as a function of stage of severity of disease, for standard automated perimetry (SAP) and short-wavelength automated
perimetry (SWAP) is shown. Boxplot limits represent the 15
th,2 5
th,5 0
th,7 5
th and 85
th percentiles.
doi:10.1371/journal.pone.0039944.g002
Visual Field Loss in AMD
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calculated. Frequency of defect maps were constructed from the
PD probability maps, which were used in preference to the total
deviation analysis as they were less variable and less likely to be
affected by the possible presence of diffuse lenticular changes.
Concentric sectors of the 10u field, based on the frequency of PD
defects, were used to evaluate the unweighted MD and change in
MD with stage. We then derived a new index, the AMD Severity
Index, using a weighted scoring system based on the PD defects
and their locations within the 10u field. The Severity Index was
examined for change with stage of AMD.
Results
Visual field data from 27 eyes of 27 patients and 22 eyes of 22
normal subjects, were included in the analysis. There were 7 eyes
Table 3. Kruskal-Wallis test of significant variation in visual
field measures with advancing stage of AMD.
MD PSD LSV
No. PD
Defects
Severity
Index
SAP Chi-square 19.630 18.605 17.597 21.032 23.038
p ,0.001 ,0.001 ,0.001 ,0.001 ,0.001
SWAP Chi-square 22.095 26.576 23.878 26.765 28.797
p ,0.001 ,0.001 ,0.001 ,0.001 ,0.001
doi:10.1371/journal.pone.0039944.t003
Table 4. Post hoc analyses (Mann-Whitney U test with Bonferroni adjustment) to detect significant differences in visual field
measures between AMD stages and normal.
SAP
MD
Stage
0–1
Stage
2–3
Stage
4
SWAP
MD
Stage
0–1
Stage
2–3
Stage
4
0.129 0.221 ,0.001 Normal 0.098 0.017 ,0.001 Normal
0.905 ,0.001 Stage
0–1
0.251 ,0.001 Stage
0–1
0.003 Stage 2–3 0.006 Stage 2–3
SAP PSD Stage
0–1
Stage 2–3 Stage 4 SWAP PSD Stage 0–1 Stage 2–3 Stage 4
0.785 0.296 ,0.001 Normal 0.539 ,0.001 ,0.001 Normal
0.321 ,0.001 Stage 0–1 0.004 0.001 Stage
0–1
0.002 Stage 2–3 0.025 Stage 2–3
SAP LSV Stage
0–1
Stage 2–3 Stage 4 SWAP LSV Stage 0–1 Stage 2–3 Stage 4
0.384 0.039 ,0.001 Normal 0.042 0.001 ,0.001 Normal
0.219 0.001 Stage 0–1 0.251 0.001 Stage 0–1
0.004 Stage 2–3 0.018 Stage 2–3
SAP No. PD
defects
Stage
0–1
Stage 2–3 Stage 4 SWAP No. PD
defects
Stage 0–1 Stage 2–3 Stage 4
0.744 0.020 ,0.001 Normal 0.337 ,0.001 ,0.001 Normal
0.067 ,0.001 Stage 0–1 0.005 0.001 Stage 0–1
0.007 Stage 2–3 0.013 Stage 2–3
SAP Severity
Index
Stage 0–1 Stage 2–3 Stage 4 SWAP Severity
Index
Stage 0–1 Stage 2–3 Stage 4
0.313 0.008 ,0.001 Normal 0.183 ,0.001 ,0.001 Normal
0.032 ,0.001 Stage 0–1 0.003 ,0.001 Stage 0–1
0.009 Stage
2–3
0.013 Stage 2–3
Results show the p-values for the mean deviation (MD), pattern standard deviation (PSD), local spatial variability (LSV), number of pattern deviation (PD) defects and
AMD Severity Index. Significant differences are in bold and have a conservative Bonferroni adjustment for multiple comparisons.
doi:10.1371/journal.pone.0039944.t004
Figure 3. Coefficient of variation (%) map for SAP and SWAP.
Mean coefficients of variation for the AMD patients and normal subjects
are shown. Maps are displayed as a right eye.
doi:10.1371/journal.pone.0039944.g003
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stage 4. Data from stages were combined by the following
grouping: stages 0–1, stages 2–3 and stage 4.
Change in visual field measures with stage
Compared to normal subjects mean sensitivity (MS) values were
decreased and SDs were increased in the AMD patients (Table 2).
Figure 2 shows the measures MD, PSD, LSV and number of PD
defects for normal and AMD subjects. Patients at stages 2–3 and 4
showed a greater variability than those at 0–1 and normal subjects.
All measures varied significantly (Kruskal-Wallis test) with the
stage of AMD for both SAP and SWAP (Table 3). A greater
number of post hoc differences (Mann-Whitney U test with
Bonferroni adjustment; Table 4) were noted between subject
groups for SWAP than for SAP, for the PSD and the LSV.
Overall, SWAP detected more differences from normal than SAP.
In SWAP, the MD had the fewest significant differences from
normal. In SAP more significant differences from normal were
evident for the Severity Index.
There were significant correlations between LSV and PSD for
SAP (Spearman’s rho=0.455, p=0.001) and SWAP (rho=0.768,
p,0.001).
Coefficient of Variation
As expected, the AMD group yielded lower MS and greater
SDs than normal group for SAP and SWAP (Table 2). Variability
was compared using the coefficient of variation statistic [26,27]
(SD/mean, expressed as %), which represents a normalised
measure of dispersion such that distributions which differ in the
magnitude of their measurement scales may be compared.
SWAP consistently revealed greater coefficients of variation
than SAP (Figure 3). The AMD patients had higher values than
normal. At AMD stages 0–1, mean coefficients of variation were
only slightly greater than normal (normals: SAP 563% SWAP
1662%; Stage 0–1: SAP 663%, SWAP 2165%) but at stage 4
large values were exhibited (SAP 44620%; SWAP 105689%).
Frequency of Defect
The frequency of defect maps (Figure 4) represent the
percentage of eyes at each stimulus location with PD defects.
SWAP defects occurred more frequently than SAP defects in early
AMD. For late stage AMD (stage 4), for both perimetry types, 70–
80% of eyes had defects within the central 5u. Enlargement of a
central scotoma was noted with progressing stage of disease. The
increase in frequency of defects with worsening disease stage
occurred at an earlier stage in SWAP than in SAP.
Sector Analysis
Based on the frequency of defect maps, the field was divided
into the following sectors: centre, middle and periphery (eccen-
tricities: 1.4u, 3.2–7.1u and 7.1–9.1u respectively; Figure 5 Top).
For AMD patients, central sector MD values were worse than the
peripheral values for both SAP and SWAP (Figure 5 Middle). For
the normal group, MD values remained uniform across all sectors.
Figure 5 (Bottom) shows the regression slope of MD as a function of
stage for each sector for SAP and SWAP. The most rapid
sensitivity loss occurred in the centre and the slowest in the
periphery.
AMD Severity Index
Based on our sector analysis and frequency of defect maps, a
Severity Index of AMD visual field loss was derived (Equation 1)
[34]. Visual field sectors were weighted by their location within the
10u field and multiplied by a depth defect score according to the
PD probability value (Figure 6). Centrally located defects and
more severe probability values carried a greater weight. The sum
was then divided by the maximum possible score to give the
Severity Index ranging between 0 (no field loss) and 1 (maximum
defects across the entire field).
Severity Index~Spatial Weight|PD Depth
Weight Ceiling Score
ð1Þ
A larger Severity Index (Figure 6 Bottom) in SWAP than in SAP
for each AMD group indicated deeper and more extensive
sensitivity loss in SWAP. Severity scores varied significantly with
stage of disease for SAP and SWAP (Table 3). Post hoc analysis
(Table 4) revealed significant differences between normal subjects
and AMD patients at stages 2–3 and 4, in SAP and in SWAP.
Visual Acuity
Figure 7 shows the visual acuities in the normal subjects and
AMD patients. Visual acuities varied significantly with stage of
AMD (Kruskall-Wallis test: Chi-square=28.09, p,0.001). A
greater number of post hoc differences from normal (Mann-
Whitney U test with Bonferroni adjustment; Figure 7) were found
than for perimetry.
Discussion
In this cross-sectional study of patients with AMD, sensitivity
loss in 10–2 SAP and SWAP visual fields increased with increased
Figure 4. Frequency of defect maps. Frequency of defect maps
show the % of eyes at each stimulus location which have significant
defects on PD analysis for SAP and SWAP as a function of stage of
disease. Maps are displayed as a right eye.
doi:10.1371/journal.pone.0039944.g004
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variability in sensitivity in the AMD patient group compared to
the normal group is consistent with previous studies [3,4,5,6,9].
We quantified the visual field loss as a function of stage of AMD
and found that the changes in SWAP were more significant than
those in SAP. SWAP had a greater capability in detecting
differences between the AMD groups and differences from
normal, than SAP. Previous studies of blue-on-yellow perimetry
in AMD [5,6] did not compare results to SAP, however in patients
with diabetes, sensitivity loss in the 10–2 visual field, due to
structural change, was better detected by SWAP than SAP
[23,35,36,37]. The SWS pathway is vulnerable to a variety of
retinal disease implying that SWS pathway sensitivity loss occurs at
multiple sites of damage [38]. Possible explanations include
reduced redundancy due to the sparse SWS system [39] and/or
the smaller response range of the SWS cone system [40].
A secondary aim was to examine the location of visual field loss
within the 10u field. A central scotoma within 5u was demonstrated
in late stage AMD, supportive of previous findings of reduced
SWS in the central compared to the peripheral 10u field in AMD
[5]. Others have indicated paracentral scotoma and preservation
of central vision in AMD [41,42], or no difference between central
and peripheral sensitivity in the 10u SWAP field [6]. Possible
explanations for these varied results include differences in
instrumentation, sample sizes, classification of AMD and analyses.
In fact, we found that the most vulnerable region to AMD
related sensitivity loss was the central 1u, in which the change was
23.9 dB per stage in SAP and 24.9 dB in SWAP. Our results
suggested a symmetrical defect, from which the Severity Index was
derived, to classify visual field defects on a continuous scale. In
SAP, the Severity Index detected the most differences between
groups. Thus, it may be a useful method for monitoring
longitudinal progression of the visual field in AMD. From our
findings, a Severity Index .0.1 in SAP and .0.2 in SWAP
appeared abnormal, however a larger study is required to
investigate this.
All visual field measures varied significantly with increasing
stage of disease, however there was some functional overlap
Figure 5. Sector analysis. Top: Sector arrangement of the 10–2 stimulus locations. Middle: The group mean MD in each sector for SAP and SWAP
for normal and AMD subjects is displayed. Bottom: The scatterplot of MD as a function of stage of AMD shows the slope of univariate linear regression
(dB per stage), in each sector for SAP and SWAP.
doi:10.1371/journal.pone.0039944.g005
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loss, such as the PSD and number of PD defects, demonstrated
greater capability in detecting AMD subjects from normal. In a
previous study [23], detection of focal loss by the number of PD
defects in SWAP, had a stronger relationship with diabetic
retinopathy than SAP.
Of the focal indices, LSV is less common but statistically less
manipulated than PSD, as well as significantly correlated with
PSD. LSV is less influenced by pre-receptoral absorption, i.e.
macular pigment and lenticular changes, which limit the
interpretation of SWAP. Although the effect of lenticular
absorption was minimised by our exclusion criteria, mild
absorption and macular pigment effects may have influenced the
SWAP data. However, significant attenuation of SWAP thresholds
by macular pigment was not evident from normal defect maps
(Figure 4), nor in our normal database. Correcting for macular
pigment, which has a high within-subject variability [43], would
artificially increase perimetric sensitivities and alter normal
prediction limits. Since the effects of pre-receptoral absorption
on SWAP are symmetrical and diffuse, a statistical approach has
been recommended to separate focal loss [43,44] and our results
support the conclusion that focal loss is of greater importance in
AMD.
A limitation of SWAP was that overall larger coefficients of
variation were found than in SAP (Figure 3), similar to previous
findings [26]. However, this finding was skewed by large values at
stages 3 and 4, where greater variability would be expected in
scotomatous locations. In fact, coefficients of variation at earlier
stages were near normal for both perimetry types, indicating
SWAP as a reliable method to examine early stage AMD patients
with minimal lens opacities.
In our study SWAP analysis had a high correlation with visual
acuity as a means of detecting AMD and this raises the question as
to what extra value SWAP measurement adds in assessing patients
with AMD. It is known that central perimetry in AMD gives
information about the spatial extent and depth of central visual
Figure 6. Calculation of Severity Index and change in Severity Index with stage of AMD. Based on Pattern Deviation (PD) maps, visual
field sectors were weighted whereby the greatest weight corresponded to the central sector (Spatial Location Weight). This was then multiplied by a
depth defect score according to the PD probability value (Pattern Deviation Weight). Middle, box: Example calculation: the sum was then divided by
the maximum possible score to give the Severity Index ranging between 0 and 1, where 0 indicates no field loss and 1 indicates maximum defects
across the entire field. Bottom: Boxplots representing the change in Severity Index as a function of stage of severity of disease, for standard perimetry
(SAP) and short-wavelength automated perimetry (SWAP). Boxplot limits represent the 15
th,2 5
th,5 0
th,7 5
th and 85
th percentiles.
doi:10.1371/journal.pone.0039944.g006
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possibilities of medical intervention available, this aspect of visual
function measurement is likely to become important. In fact, visual
acuity appeared to better differentiate between early stage AMD
and normal, than perimetry. Therefore the value of SAP and
SWAP analysis in AMD is in research, rather than as a diagnostic
tool.
Limitations of the study were the small number of eyes at
individual stages, which led to the grouping of stages and the cross-
sectional design of the study. The difference in SAP and SWAP
normative databases limits the analyses, however use of the HFA
Statpac analysis is standard in clinical practice and provides
greater accuracy than collection of new SAP normative data. A
longitudinal study in a larger sample, following visual field
progression over several years is warranted, in which the Severity
Index could be used to measure field defects on a continuous scale.
In a larger sample it would be possible to differentiate results
between late stage patients with geographic atrophy and choroidal
neovascularisation. Specific consideration in a progression study,
would be necessary to account for worsening cataracts and
potential involvement of fixation later in the disease, which may
affect the interpretation of visual field results. Furthermore, visual
field testing may be useful in assessing the effectiveness of novel
treatments in either preserving or improving visual field loss in
patients with AMD, enrolled in a clinical study under appropriate
exclusion criteria. Due to the strict exclusion criteria of our study,
our findings are limited to AMD subjects suitable to visual field
testing, i.e. those who have foveal fixation and clear ocular media.
The results present evidence of a relationship between the
SWAP visual field and severity of AMD, whereby sensitivity
declined with advancing stage of AMD. SWAP had greater
capability in detecting early AMD than SAP. The importance of
early detection of functional change in AMD is clinically relevant
to possible earlier intervention or lifestyle changes. Sensitivity loss
in AMD was focal in nature and the central field became less
uniform as stage increased. SWAP defects occurred at similar
locations but were deeper and wider than corresponding SAP
defects. Although not all patients are suitable for SWAP
examinations, our findings support it as a useful tool in research
studies of visual loss in AMD.
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